FY2022 EPS Estimates for Corbus Pharmaceuticals Holdings Inc Raised by B. Riley (CRBP)

Share on StockTwits

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) – B. Riley boosted their FY2022 earnings estimates for shares of Corbus Pharmaceuticals in a report issued on Wednesday, March 20th. B. Riley analyst G. Zavoico now expects that the biopharmaceutical company will post earnings per share of $3.53 for the year, up from their previous estimate of $3.25. B. Riley also issued estimates for Corbus Pharmaceuticals’ FY2023 earnings at $7.58 EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.07). Corbus Pharmaceuticals had a negative return on equity of 116.34% and a negative net margin of 1,154.52%. The firm had revenue of $1.93 million during the quarter, compared to the consensus estimate of $1.99 million.

Other analysts have also issued research reports about the company. ValuEngine lowered Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. HC Wainwright initiated coverage on Corbus Pharmaceuticals in a report on Wednesday, December 26th. They issued a “buy” rating and a $24.00 price objective for the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Corbus Pharmaceuticals in a report on Tuesday, March 12th. Zacks Investment Research lowered Corbus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 13th. Finally, BidaskClub upgraded Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Corbus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $24.36.

Shares of CRBP opened at $7.68 on Thursday. Corbus Pharmaceuticals has a one year low of $4.50 and a one year high of $9.11. The firm has a market capitalization of $481.03 million, a P/E ratio of -7.84 and a beta of 2.17.

Several institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Corbus Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 542,722 shares of the biopharmaceutical company’s stock valued at $3,169,000 after acquiring an additional 28,582 shares in the last quarter. Millennium Management LLC lifted its position in shares of Corbus Pharmaceuticals by 331.4% in the fourth quarter. Millennium Management LLC now owns 130,245 shares of the biopharmaceutical company’s stock valued at $761,000 after acquiring an additional 100,051 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Corbus Pharmaceuticals by 357.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,973 shares of the biopharmaceutical company’s stock valued at $99,000 after acquiring an additional 13,265 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new position in shares of Corbus Pharmaceuticals in the fourth quarter valued at about $3,125,000. Finally, Bank of America Corp DE lifted its position in shares of Corbus Pharmaceuticals by 6.7% in the fourth quarter. Bank of America Corp DE now owns 37,304 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 2,335 shares in the last quarter. Institutional investors and hedge funds own 40.27% of the company’s stock.

In related news, insider Barbara White bought 4,638 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were bought at an average cost of $6.47 per share, for a total transaction of $30,007.86. Following the completion of the transaction, the insider now owns 184,159 shares of the company’s stock, valued at $1,191,508.73. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have purchased 8,668 shares of company stock worth $56,923 over the last quarter. 12.60% of the stock is owned by company insiders.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases.

Featured Article: What is the Difference Between Common Shares and Convertible Shares?

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Albireo Pharma Inc  Expected to Announce Earnings of -$1.44 Per Share
Albireo Pharma Inc Expected to Announce Earnings of -$1.44 Per Share
Dynex Capital Inc  Plans Monthly Dividend of $0.18
Dynex Capital Inc Plans Monthly Dividend of $0.18
Insider Buying: Ipsidy Inc  CFO Acquires $25,000.00 in Stock
Insider Buying: Ipsidy Inc CFO Acquires $25,000.00 in Stock
Kenneth Michael Dedeluk Sells 5,000 Shares of Computer Modelling Group Ltd.  Stock
Kenneth Michael Dedeluk Sells 5,000 Shares of Computer Modelling Group Ltd. Stock
Tabula Rasa HealthCare Inc  Director Sells $51,520.00 in Stock
Tabula Rasa HealthCare Inc Director Sells $51,520.00 in Stock
Insider Buying: Immunomedics, Inc.  Insider Purchases $66,750.00 in Stock
Insider Buying: Immunomedics, Inc. Insider Purchases $66,750.00 in Stock


 
© 2006-2019 Zolmax.